At MSF, we’re delighted to announce that Armelle Pindon, our Chief Scientific Officer, is part of the external advisory committee for the 3D-MOFIB program at NCATS (The National Center for Advancing Translational Sciences), a US government research agency under the National Institutes of Health (NIH).

The program stands for "An Integrated Multiorgan Platform of 3D Microtissues to Model and Understand Interindividual Drug Susceptibility in Fibrotic Pathologies," which, in plain language, means they are developing new ways to better simulate human biology and reduce reliance on animal models. This process will take time, which is why scientists are still using animal models today, but we’re fully on board with advancing these new technologies.

You’ll notice fibrotic in the title, and this is what we’re all excited about. The platform will model fibrotic pathways across multiple organs, which is very relevant to the research we’re doing with Myhre syndrome. From a broader perspective, this continues to signal significant investment in anti-fibrotic technologies and compounds, recognizing the large unmet need for fibrosis treatments across many diseases.

We’re delighted that Armelle is part of the conversation on advancing science and is at the forefront of understanding new fibrotic technologies. Congratulations Armelle!